Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 5/20 | 0.47 |
| ▸ | PPARD | Q03181 | 4/20 | 0.47 |
| ▸ | PPARA | Q07869 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29485563 | 0.87 | TDP1 (0.61) | TDP1ACACBPPARDPPARA | |
| SCHEMBL6619964 | 0.86 | TDP1 (0.53) | TDP1ACACBPPARDPPARATSHR | |
| SCHEMBL19196477 | 0.85 | S1PR3 (0.60) | TDP1ACACBPPARDPPARATSHR | |
| SCHEMBL7001607 | 0.82 | ALDH1A1 (0.57) | TDP1PPARDPPARATSHRLMNA | |
| SCHEMBL3622690 | 0.81 | LMNA (0.44) | TDP1ACACBPPARDPPARATSHR | |
| SCHEMBL3622689 | 0.81 | LMNA (0.44) | TDP1ACACBPPARDPPARATSHR | |
| SCHEMBL5521975 | 0.81 | LMNA (0.44) | TDP1ACACBPPARDPPARATSHR | |
| SCHEMBL5693653 | 0.77 | S1PR1 (0.51) | TDP1ACACBPPARDPPARATSHR | |
| SCHEMBL19311800 | 0.76 | TP53 (0.60) | TDP1ACACBPPARDPPARA | |
| SCHEMBL22637183 | 0.76 | S1PR3 (0.55) | TSHRLMNAS1PR3GABRB1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | MMP12, TIMP3, MMP9 | TDP1 2141/4885ACACB 2908/4885PPARD 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.